Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Research & Development · Q2 FY2027 · quarter ended Sep 2026

Research & development declines year over year

Q2 FY2027 research & development of ₹5.23B fell 15.7% year over year, behind the -13.8% change in trailing-twelve-month research & development. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Research & development amounted to 7.2% of revenue in FY2026, down 1.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -15.7% toward the trailing-twelve-month pace of -13.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
₹5.23B-9.9% QoQ
Last fiscal yearMar 2026
₹25.31B-7.5% YoY
LTMSep 2026
₹22.73B-13.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.7%——
1 year-7.5%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

INR · from the income statement

Latest · FY2026
25.31B INR
Year-over-year change
-7.5%
4-year CAGR
+9.7%

Research & Development vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.8% is the 6th highest of 7, against a peer median of +8.6%.
  • Research & development amounts to 6.9% of revenue for RDY, versus a peer median of 5.7%.
RDY Competitors
Research & Development for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹22.73B INR-13.8%+9.3%6.9%
VTRSViatris Inc.LTM Jun 2026$1.02B USD+20.8%+13.4%6.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$995M USD-0.7%+6.5%5.7%
BHCBausch Health Companies Inc.LTM Jun 2026$634M USD+1.3%+5.9%5.8%
HLNHaleon plcLTM Jun 2025£459.5M GBP—+0.9%2.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$177.66M USD-15.0%-3.7%5.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$92.49M USD+20.2%+4.7%12.8%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$51.7M USD+15.8%+32.3%5.6%
Peer median (excluding RDY) —+8.6%+5.9%5.7%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.